FLAD

FLAD. FLAD, or FAD synthase, is a critical enzyme encoded by the *FLAD1* gene in humans that is responsible for the biosynthesis of the essential cofactor flavin adenine dinucleotide (FAD). This final step in the riboflavin (vitamin B2) metabolism pathway is vital for cellular energy production and redox homeostasis. The enzyme's activity is fundamental to the function of numerous flavoproteins involved in crucial metabolic and catabolic processes across all tissues.

Overview

FLAD, or FAD synthase, is a bifunctional enzyme that catalyzes the dual adenylylation and phosphorylation reactions required to convert riboflavin into FAD via the intermediates flavin mononucleotide (FMN) and adenosine triphosphate (ATP). It is the terminal enzyme in the FAD biosynthesis pathway and is localized primarily within the cytosol and mitochondria, reflecting the organelle's high demand for flavoproteins. The protein exists in multiple isoforms generated through alternative splicing, which dictate its subcellular targeting and functional specificity. Its activity is tightly regulated, as FAD is a prosthetic group for a vast array of enzymes central to life, including those in the electron transport chain and DNA repair pathways.

History

The enzymatic activity for FAD synthesis was first identified and studied in bacteria and yeast models, such as *Saccharomyces cerevisiae*, during mid-20th century investigations into B vitamin metabolism. The human gene, *FLAD1*, was later cloned and characterized in the early 2000s following advances in genome sequencing projects like the Human Genome Project. Key research from institutions like the University of Milan and the National Institutes of Health elucidated the enzyme's structure and its critical role in human health. The association between mutations in *FLAD1* and human myopathy was a significant discovery, first reported in studies of patients with lipid storage myopathy and multiple acyl-CoA dehydrogenase deficiency (MADD)-like symptoms, linking its dysfunction to specific inborn errors of metabolism.

Structure and function

The human *FLAD1* gene is located on chromosome 1 and encodes a protein with distinct catalytic domains: an FMN adenylyltransferase domain and a FAD pyrophosphorylase domain. The full-length isoform localizes to the mitochondria, guided by an N-terminal mitochondrial targeting sequence, while shorter isoforms, such as the cytosolic isoform 2, result from alternative transcription start sites. The enzyme's mechanism involves two sequential steps: first, it adenylylates FMN to form FAD, and second, it can also generate FMN from riboflavin and ATP. Its function is essential for activating succinate dehydrogenase, acyl-CoA dehydrogenase, and glutathione reductase, among many other flavoenzymes. The structure has been informed by homology with bacterial counterparts like the Fad1 protein in *Bacillus subtilis*.

Clinical significance

Deficiencies in FLAD function are linked to severe autosomal recessive disorders, primarily a form of lipid storage myopathy that presents as a multiple acyl-CoA dehydrogenase deficiency (MADD) phenotype. Patients typically exhibit hypotonia, muscle weakness, hypoglycemia, and metabolic acidosis, often diagnosed in infancy or early childhood. These conditions, sometimes classified as riboflavin-responsive MADD, can be detected through tandem mass spectrometry revealing characteristic acylcarnitine profiles. Treatment often involves high-dose supplementation with riboflavin and carnitine, which can ameliorate symptoms by bypassing the enzymatic block. The disorder highlights the critical role of FLAD in fatty acid oxidation and amino acid catabolism, with severe cases involving cardiomyopathy and respiratory failure.

Research and applications

Current research on FLAD focuses on understanding the genotype-phenotype correlations of *FLAD1* mutations and exploring novel therapeutic strategies beyond vitamin supplementation. Studies utilizing knockout mouse models and patient-derived fibroblast lines are investigating the pathophysiological mechanisms of FAD deficiency and its impact on mitochondrial dysfunction. Its role is also being explored in broader contexts, such as cancer metabolism, as some tumor cells upregulate flavoprotein expression. Furthermore, the enzyme is a target for drug discovery in infectious diseases, given that the FAD biosynthesis pathway in pathogens like *Plasmodium falciparum* differs from that in humans. Advances in structural biology, including potential X-ray crystallography studies of human FLAD, aim to inform the design of specific modulators for both clinical and research applications.

Category:Human proteins Category:Enzymes Category:EC 2.7.7